ALT Q3 2018 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-42.6% YoY

Gross Profit

-$2M-79.5% margin

Operating Income

-$4M-154.0% margin

Net Income

-$2M-89.2% margin

EPS (Diluted)

$-1.78

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$95,532

Balance Sheet

Total Assets

$53M

Total Liabilities

$13M

Stockholders' Equity

$40M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$5M	-42.6%
Gross Profit	-$2M	-$1M	-59.4%
Operating Income	-$4M	-$31M	+86.9%
Net Income	-$2M	-$30M	+92.1%

Revenue Segments

Grant

$3M100%

License and Service

$4,9470%